In the latest post on the the IVI-sponsored Health Affairs blog series, Neeraj Sood, Tiffany Shih, Karen Van Nuys and Dana Goldman present the findings of their study examining the flow of funds in the pharmaceutical distribution system, suggesting that greater transparency and granularity would be beneficial in the reporting of financials from all sectors. [...]
In a post on the the IVI-sponsored Health Affairs blog series, Henry Grabowski and Richard Manning offer a rebuttal to a recent Health Affairs blog commentary by Nancy Yu, Zachary Helms, and Peter Bach on the subject of drug pricing. In their rebuttal, Grabowski and Manning caution that the premise of the earlier blog post [...]
In a recent post on the IVI-sponsored Health Affairs blog series, Michael Carrier and Steve Shadowen examine the practice of "product hopping," in which drug manufacturers can delay a generic introduction through product reformulation. In addition to presenting some of the prevailing issues before the courts, the authors also propose a new framework to keep the [...]
In the latest post on the IVI-sponsored Health Affairs blog series, Chronis Manolis, C. Bernie Good and William Shrank discuss current approaches to curbing rampant opioid abuse, including the mandating of coverage for abuse-deterrent opioids. The authors make the case that this tactic would be non-effective, costly and would distract from arriving at more comprehensive solutions [...]
In a post on the IVI-sponsored Health Affairs blog series,Josh Seidman, Margaret Anderson, Domitilla Masi, Melea Atkins and Maureen Japha examine the role of patient perspectives in assessing value in healthcare, focusing on the Avalere-FasterCures Patient-Perspective Value Framework as an example of progress toward a more patient-centered approach to value assessment. Read the full article [...]
In the latest post on the IVI-sponsored Health Affairs featured blog series, Seth Seabury and Neeraj Sood examine the challenges to addressing the significant threat that antimicrobial resistant infections pose to human health. In their commentary, Seabury and Sood focus on three of the most commonly proposed policies to promote the development of new antimicrobials: market [...]
In the latest post on the IVI-sponsored Health Affairs featured blog series, Rachel Sachs addresses key provisions of the FDA's proposed user fee reauthorization bill. Included in her assessment are details of new language changes and amendments added to the bill, as well as a look forward to potential obstacles to the bill's final passage. Read [...]
In a recent post on the IVI-sponsored Health Affairs featured blog series,Thomas Hwang and Aaron Kesselheim examine proposed new legislation taxing manufacturers of pharmaceuticals with medications exhibiting significant pricing spikes. Hwang and Kesselheim break down the criteria for the tax, and also offer some insight into potential policy implications. Read the full article here. About the Health [...]
In a recent post on the IVI-sponsored Health Affairs featured blog series, IVI’s Darius Lakdawalla and Alan Balch stress the importance of incorporating the patient perspective into value assessments in healthcare, and of developing tools to help patients make value-based decisions in the marketplace. The Balch and Lakdawalla piece reflects IVI’s view that value in healthcare rests [...]
In a recent post on the IVI-sponsored Health Affairs featured blog series, Joshua Liao and Mark Pauly examine the role of government regulation of orphan drugs in rising drug prices, providing some specific examples and how they relate to the provisions of the Orphan Drug Act. Liao and Pauly also present some potential solutions to the problem, including [...]
